Clinical Efficiency of Epigam in Patients with Exacerbation of Peptic Ulcer Disease of the Stomach and Duodenum

Bulletin of Experimental Biology and Medicine

Volumn 135-136, Issue 7, 2003, Pages 159-162

  Bakumov, P A ^a   Shchepotkin, I V ^a   Dugina, Yu L ^b   Epstein, O I ^b   Sergeeva, S A ^b  

^a VOLGOGRAD STATE MEDICAL UNIVERSITY   (Russian Federation)

^b Materia Medica Holding R   (Russian Federation)

Author keywords

Antibodies against histamine; Antiulcer therapy; Peptic ulcer disease; Ultralow doses

Indexed keywords

AMOXICILLIN; ANTIBODY; EPIGAM; HISTAMINE ANTIBODY; HOMEOPATHIC AGENT; METRONIDAZOLE; RANITIDINE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DUODENUM; FEMALE; HEALING; HELICOBACTER INFECTION; HUMAN; MALE; PEPTIC ULCER; STOMACH MUCOSA;

HELICOBACTER; HELICOBACTER PYLORI;

EID: 0346373591     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024752829504     Document Type: Article

References (4)

1. P. Ya. Grigor'ev, Lech. Vrach, No. 1, 509 (1998).
2. V. T. Ivashkin, F. Megro, and T. L. Lapina, Helicobacter pylori: Revolution in Gastroenterology [in Russian], Moscow (1999).
3. O. I. Epstein, S. G. Krylova, E. P. Zueva, et al., Byul. Eksp. Biol. Med., Appl. 3, 43-45 (2001).
4. T. L. Lapina, Ros. Zh. Gastroenterol. Gepatol. Koloproktol., 9, No. 2, 41-45 (1999).